文献速递炎症性肠病

综述:炎症性肠病中维多珠单抗与乌司奴单抗应答的预测因素

Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2018-02-12

本文综述了炎症性肠病(IBD)中维多珠单抗和乌司奴单抗应答预测因素的现有数据。通过PubMed检索相关研究,发现重症疾病或既往抗TNF暴露者应答维多珠单抗可能性较低,而回结肠受累、无手术史和简单表型与乌司奴单抗较好应答相关;初始应答似乎预测两种治疗更好的长期维持(P < 0.001)。免疫原性在应答中作用较小。

要点

  • 重症疾病或既往抗TNF暴露者应答维多珠单抗可能性较低。
  • 回结肠受累、无手术史和简单表型与乌司奴单抗较好应答相关。
  • 初始应答似乎预测两种治疗更好的长期维持(P < 0.001)。

核心结论

  • 随着IBD新生物疗法增多,识别最可能从特定药物获益的患者对优化治疗定位至关重要。

研究设计与样本

  • 本文为综合性文献综述,通过PubMed使用预设关键词检索有关应答预测因素的相关研究。

主要发现

  • 重症疾病(基于临床活动度和炎症生物标志物)或既往抗TNF暴露的患者应答维多珠单抗的可能性较低。
  • 在克罗恩病中,回结肠受累、无既往手术和简单表型与乌司奴单抗较好应答相关。
  • 初始应答似乎预测两种治疗更好的长期维持(P < 0.001)。
  • 与抗TNF治疗相反,免疫原性在应答中似乎作用较小。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increased knowledge of pathways involved in the pathogenesis of IBD has led to the development of new treatment options for Crohn's disease (CD) and ulcerative colitis (UC). Two new biological agents have been recently approved for IBD: vedolizumab and ustekinumab. They have different therapeutic targets (α4 β7 integrin for vedolizumab and interleukin-12/23 pathways for ustekinumab) than the primary biological class, anti-tumour necrosis factor alpha (anti-TNF) agents. As the armamentarium for IBD increases in coming years, it will become important to understand factors associated with response in order to best position and personalise therapy. AIM: To summarise the current data on predictors of response to vedolizumab and ustekinumab in IBD patients. METHODS: We conducted a comprehensive literature review. A PubMed search was performed using pre-defined key words and terms to identify relevant studies on predictors of response. RESULTS: Patients with severe disease (by clinical activity and inflammatory biomarkers), or prior anti-TNF exposure are less likely to respond to vedolizumab. Ileocolonic disease, no prior surgery and uncomplicated phenotype were associated with better responses to ustekinumab in CD. Initial response seems to predict a better long-term maintenance in both therapies (P < 0.001). Contrary to anti-TNF therapies, immunogenicity appears to play less of a role in response. CONCLUSION: As the number of new biological therapies increase in IBD, identifying patients who are most likely to benefit from specific agents is of paramount importance to help best position IBD therapies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Barré A, Colombel JF, Ungaro R, et al. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2018. PMID: 29430672. doi:10.1111/apt.14550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。